a3d00016_admin

#64 ❤️‍🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics

January 20, 20261KViews

Most people talk about lifespan. We obsess over how long we live. What actually matters is healthspan. How long we stay strong, mobile, and pain-free. Living to 90 means very little if your joints fail you at 60. At Cytonics Corporation, our mission is simple: extend healthspan by protecting the biology that makes movement…

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

January 6, 20261KViews

You may have seen the recent headlines regarding a breakthrough in "anti-aging injections" for cartilage regeneration, published in Science (Singla et al., 2025). Led by Stanford Medicine, this research identifies the inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel pathway to restore regenerative capacity in chondrocytes (the cartilage-secreting cells in joints). While the media is…

#62 🙏 Another Year Full of Gratitude

December 26, 20251KViews

As the year concludes, Joey Bose reflects on gratitude towards investors, the Cytonics community, and the dedicated team. He emphasizes the importance of long-term commitment and support in their progress. Looking ahead to 2026, he encourages everyone to cherish time with loved ones and appreciate their contributions.

#62 🙏 Another Year Full of Gratitude

December 26, 2025679Views

As the year winds down, I’ve found myself thinking less about milestones and more about people. The ones doing the work day in and day out. The ones asking good questions. The ones choosing to support something that takes patience, care, and long-term thinking. I’m deeply thankful to our investors for the trust you…

#61 🛑 Can We Stop Osteoarthritis Before It Starts?

December 20, 2025916Views

Some individuals inherit a genetic risk for osteoarthritis, potentially experiencing severe symptoms by their 40s or 50s. Early identification and treatment with alpha-2-macroglobulin (A2M) may preserve joint health and enhance quality of life. Development of CYT-108 aims to target the root cause of osteoarthritis, rather than just alleviate pain.

#60 👎 Where Big Pharma Tried And Failed

November 4, 20251KViews

Osteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials.

#60 👎 Where Big Pharma Tried And Failed

November 4, 20251KViews

Osteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials.

#59 🧬 Why is A2M being called a physiological guardian?

October 21, 2025938Views

Joey Bose, our CEO and President, breaks down why researchers have called A2M the 'physiological guardian.' A2M, or alpha-2-macroglobulin, is a natural protein found in your bloodstream that acts like a bodyguard against inflammation and joint destruction. It works as a broad-spectrum protease inhibitor and also sequesters cytokines – the same inflammatory signals you heard…

#58 🚅 Inside the Engine Room: Progress Since Our $7M Raise

October 14, 2025786Views

How Cytonics is preparing for its next regulatory milestone — from database lock to FDA engagement. It’s been just over a month since we wrapped up our $7M crowdfunding campaign — our largest and most successful raise to date — and the pace hasn’t slowed for a moment. Since then, our team has been hard…

#57: 👎 Why Cytonics Turned Down VC

August 27, 20251KViews

Cytonics rejects venture capital, believing it stifles innovation and dilutes shareholder value. Instead, they rely on over $25 million raised from individual investors who prioritize genuine progress over quick exits. With a strong community of 7,000 shareholders, they emphasize equity crowdfunding as a pathway to democratized and collaborative biotech advancement.

#56 🚗 Our CEO Delivers A Quick Message From the Road!

August 16, 20251KViews

The message emphasizes gratitude towards patients and investors who contribute to Cytonics’ mission. Highlighting milestones like treating over 10,000 patients and issuing 25 patents, it reinforces that Cytonics is community-driven and not just a typical biotech firm. The team appreciates all stakeholders and encourages further investment.

#55 🧬 Perfecting Nature’s Blueprint

July 1, 20251KViews

Cytonics has developed CYT-108, a refined version of the naturally occurring protein Alpha-2-Macroglobulin (A2M), to combat osteoarthritis. By optimizing A2M for enhanced protease inhibition, the precision-engineered biologic minimizes side effects and maximizes therapeutic potential. It’s backed by extensive scientific validation and patented for patient safety and efficacy.

#64 ❤️‍🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

#62 🙏 Another Year Full of Gratitude

#62 🙏 Another Year Full of Gratitude

#61 🛑 Can We Stop Osteoarthritis Before It Starts?

#60 👎 Where Big Pharma Tried And Failed

#60 👎 Where Big Pharma Tried And Failed

#59 🧬 Why is A2M being called a physiological guardian?

#58 🚅 Inside the Engine Room: Progress Since Our $7M Raise

#57: 👎 Why Cytonics Turned Down VC

#56 🚗 Our CEO Delivers A Quick Message From the Road!

#55 🧬 Perfecting Nature’s Blueprint

Get fresh updates

Download Exclusive Investor Presentation & Stay Updated